Medmain Inc.

【Announcement of Participation in the Japan Night – 43rd Annual J.P. Morgan Healthcare Conference】 The 43rd Annual J.P. Morgan Healthcare Conference, the largest and most informative healthcare investment symposium in the industry, will be held in San Francisco, California, USA from Monday January 13 to Thursday January 16, 2025 (local time). The event will feature global industry leaders, emerging fast-growing companies, innovative technology creators and members of the investment community. On Monday, January 13, the first day of the conference, there will be “Japan Night” where we will have a booth to introduce our “PidPort”, an AI-powered cloud system for digital pathology support. “Japan Night” is held in cooperation with the Consulate-General of Japan in San Francisco and will be attended by over 400 key figures from the biotech field, including representatives from major pharmaceutical companies, venture capitalists and start-up companies from Japan, the U.S. and around the world who attend the J.P. Morgan Healthcare Conference. The event is expected to be an significant opportunity to establish connections between Japan and the San Francisco/Silicon Valley ecosystem of healthcare and biotechnology industries. We look forward to building many fruitful relationships through this valuable opportunity, which is anticipated to enhance networking and foster synergies. Please see below for more details. Japan Night: Building a Stronger U.S.-Japan Healthcare Connection https://lnkd.in/gTqfQB7X ■Date: Monday, January 13, 2025, 4:00 pm - 6:00 pm PST ■Venue: DG717 (Digital Garage) 717 Market St, San Francisco, CA 94103 ■Organizers: Consulate-General of Japan in San Francisco, Japan Society of Northern California, Link-J (Life Science Innovation Network Japan), CIMC, Niterra, Digital Garage

【Medmain Acquires ISO/IEC 27001 Certification for an Information Security Management System】 Medmain Inc., a Japanese medtech startup that offers PidPort, an AI-powered cloud system to assist in digital pathology, is pleased to announce that as of November 4, 2024, it has acquired ISO/IEC 27001:2022 certification, the international information security management system standards. ISO27001 specifies the requirements for establishing, implementing, maintaining, and improving an information security management system and provides a risk management process so that organizations can accordingly keep their information safe. As the most internationally recognized certification for information security management, it strictly evaluates such as information security policy, security processes and security controls. Medmain has obtained ISO27001 certification to further enhance security and reliability as it handles customers’ confidential information. By obtaining the certification, Medmain has demonstrated to maintain high standards security through systematic management. We will continue to strengthen our information management and operation systems to enhance the reliability of our services to our clients and to ensure that they can use our services more safely. Overview of Certification and Registration Certification Standards：ISO/IEC 27001:2022 and JIS Q 27001:2023 Registration Number：JP24/00000322 Certified Organizations：Medmain Inc. Certification Scope：Planning, development, operation and sales of medical software products, cloud service First Registration Date：November 4, 2024 Certification Body：SGS Japan Inc.

【Notice of Acquisition of a First-Class Marketing License for Medical Devices】 Medmain Inc. is pleased to announce that it has received a business license for “a first-class marketing license for medical devices” from the Governor of Tokyo, Japan as of July 2, 2024. We are hereby granted to manufacture and sell general medical devices, controlled medical devices, and highly controlled medical devices, pursuant to the provision of Article 23-2, Paragraph 1 of “the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices". 【Overview of Marketing License for Medical Devices】 Name of Company: Medmain Inc. Date of License Issued: July 2, 2024 Category of License: a first-class marketing license for medical devices License Number: 13B1X10433 ■About Medmain Inc. Medmain Inc. has a corporate mission of “to create a world where medical services can be accessed with technology anywhere, anytime,” and develops and provides PidPort, an AI-powered cloud system that supports digital pathology, as a partner to medical professionals around the world. Medmain Inc. provides a full range of digital pathology services, starting with the digitization of histopathology slides, remote diagnosis support that connects facilities through the cloud, and the presentation of highly accurate and rapid analysis results using pathology AI, all of which are used at many facilities. In pathology AI development, which is our core technology, we have succeeded in creating a proprietary fundamental technology that accelerates AI development through transfer learning, and we are now capable of detecting cancer in multiple organs throughout the body. We will keep promoting social implementation of pathology AI in the field of diagnosis support, using our product “PidPort,” an AI-powered cloud system to assist in digital pathology.

【We are on the stage in Silicon Valley; that Japan Innovation Campus, by the Ministry of Economy, Trade, and Industry of Japan, for the Japanese startups】 Medmain Inc., a provider of the digital pathology support solution “PidPort,” is pleased to announce that we have been selected as a coworking member of “Japan Innovation Campus,” a new base for Japanese startups established in Silicon Valley, USA by the Ministry of Economy, Trade, and Industry (Head Office: Tokyo, Japan; hereinafter “METI,”) which is one of the government agencies of Japan, responsible for national policy formulation and implementation related to Japan’s economy, trade, and industry such as renewable energy, robotics industry, environmental policies and medical devices. Through our activities at this base, we will accelerate our business expansion in the United States. ■About Japan Innovation Campus METI has established “Japan Innovation Campus” in Silicon Valley (City of Palo Alto), the U.S., one of the most developed startup ecosystems in the world, as a joint effort with the local public, industrial, and academic sectors to support Japanese startups aiming to expand business overseas. METI will work together with local private companies, including accelerators and venture capital firms, world top-class universities and academic institutions, including Stanford University and the University of California, Berkeley, and administrative organizations, including the Japan External Trade Organization (JETRO), to support Japanese startups in fund raising and business development in the U.S., and also support Japanese companies in collaborating with startups and venture capital firms in the U.S., and other activities. For more details: https://lnkd.in/ge99sPfa #Pathology #DeepLearning #AI #Medmain

【Promoting the Social Implementation of Pathological AI Developed by JP-AID and the University of Tokyo】 Dr. Hiroyuki Abe, Senior lecturer at the University of Tokyo (Head Office: Tokyo, Japan), gave an announcement on the achievements and future prospects of the Japan Pathology AI Diagnostics Project (hereinafter “JP-AID”), at the 69th Autumn Annual Meeting of the Japanese Society of Pathology. The JP-AID is a project initiated by the Japanese Society of Pathology (Head Office: Tokyo, Japan) with support from Japan Agency for Medical Research and Development (Head Office: Tokyo, Japan; hereinafter “AMED”). As a JP-AID project, the University of Tokyo and the National Institute of Informatics (Head Office: Tokyo, Japan; hereinafter “NII”) have jointly developed AI to assist in the pathological diagnosis of gastric biopsies. It was announced at the meeting that this AI-powered system for gastric biopsies will be developed as a software as medical device (SaMD) to support pathological diagnosis with the aim of obtaining regulatory approval and implementing it in society, in the “Medical Innovation Promotion Project (Development and Commercialization Project)” selected by AMED. Medmain Inc. will help reduce the workload of busy pathologists with this AI to support pathological diagnosis. It is also expected to promote the elimination of the cancer-care disparity by incorporating it into the telepathology diagnosis for doctors. #Pathology #DeepLearning #AI #Medmain いいね！ コメントする シェア